1. Home
  2. MSM vs CRNX Comparison

MSM vs CRNX Comparison

Compare MSM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MSC Industrial Direct Company Inc.

MSM

MSC Industrial Direct Company Inc.

HOLD

Current Price

$89.29

Market Cap

4.9B

Sector

Industrials

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.25

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSM
CRNX
Founded
1941
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
3.9B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
MSM
CRNX
Price
$89.29
$36.25
Analyst Decision
Hold
Strong Buy
Analyst Count
5
9
Target Price
$91.00
$74.78
AVG Volume (30 Days)
530.7K
1.0M
Earning Date
04-01-2026
05-07-2026
Dividend Yield
3.79%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
$3,363,817,000.00
$1,039,000.00
Revenue This Year
$5.88
$722.66
Revenue Next Year
$5.16
$183.79
P/E Ratio
$98.67
N/A
Revenue Growth
4.99
N/A
52 Week Low
$68.10
$24.10
52 Week High
$96.99
$57.99

Technical Indicators

Market Signals
Indicator
MSM
CRNX
Relative Strength Index (RSI) 48.54 37.03
Support Level $87.44 $33.23
Resistance Level $89.68 $37.23
Average True Range (ATR) 2.92 1.49
MACD -0.05 0.22
Stochastic Oscillator 50.34 53.29

Price Performance

Historical Comparison
MSM
CRNX

About MSM MSC Industrial Direct Company Inc.

Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: